文献速递心律失常

极低血栓栓塞风险房颤患者口服抗凝的影响

Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk.
PubMed 文献 · Heart · 2019-12-05

基于GARFIELD-AF注册研究,分析CHA2DS2-VASc评分0分(男)或1分(女)的房颤患者中口服抗凝(OAC)的使用原因及影响。44%的患者接受了OAC;持续/永久性房颤和年龄增长至65岁与OAC使用相关,而联用抗血小板治疗呈负相关。无论是否使用OAC,血栓栓塞和出血事件均很少,凸显该人群低风险。

要点

  • 极低血栓风险房颤患者中44%接受OAC,与指南推荐相悖。
  • 持续/永久性房颤和年龄增长至65岁与OAC使用正相关。
  • 联用抗血小板治疗与OAC使用呈负相关。

核心结论

  • 极低血栓栓塞风险房颤患者中近半数接受OAC,与指南推荐相反。
  • 无论是否使用OAC,血栓栓塞和出血事件均很少,提示该人群风险低。

研究设计与样本

  • 基于GARFIELD-AF注册研究,纳入CHA2DS2-VASc评分0分(男)或1分(女)的房颤患者2224例。
  • 比较OAC使用与否的基线特征及临床结局。

主要发现

  • 44%的低CHA2DS2-VASc患者接受了OAC。
  • 调整模型中,年龄增长至65岁(OR 1.31,95%CI 1.19-1.44)、持续房颤(OR 3.25,95%CI 2.44-4.34)和永久房颤(OR 2.29,95%CI 1.59-3.30)与OAC使用相关。
  • 联用抗血小板治疗与OAC使用呈负相关(OR 0.21,95%CI 0.17-0.27)。
  • 2年粗发生率(每100人年)OAC vs 未OAC:非出血性卒中或体循环栓塞0.32(95%CI 0.14-0.71)vs 0.30(95%CI 0.14-0.63);大出血0.21(95%CI 0.08-0.57)vs 0.17(95%CI 0.06-0.46);心血管死亡0.26(95%CI 0.11-0.64)vs 0.26(95%CI 0.12-0.57);全因死亡0.74(95%CI 0.44-1.25)vs 0.99(95%CI 0.66-1.49)。

临床怎么用

  • 对于CHA2DS2-VASc评分0分(男)或1分(女)的房颤患者,应遵循指南,通常不推荐常规OAC。
  • 需注意持续/永久性房颤和年龄增长可能促使OAC使用,但应评估血栓栓塞风险。
  • 联用抗血小板治疗可能降低OAC使用,需权衡利弊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate reasons for and impact of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) at very low thromboembolic risk. METHODS: Individuals with CHA2DS2-VASc score 0 (men) or 1 (women) from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) were studied. Baseline characteristics according to OAC use were evaluated by logistic regression analysis. Non-haemorrhagic stroke or systemic embolism, major bleeding, cardiovascular and all-cause mortality were compared. RESULTS: From 2224 low CHA2DS2-VASc patients in GARFIELD-AF, 44% received OAC. In an adjusted model, increasing age up to 65 years (OR (95% CI)=1.31 (1.19 to 1.44)) and persistent AF (OR (95% CI)=3.25 (2.44 to 4.34)) or permanent AF (OR (95% CI)=2.29 (1.59 to 3.30)) versus paroxysmal/unclassified AF were associated with OAC use. Concomitant antiplatelet therapy (OR (95% CI)=0.21 (0.17 to 0.27)) was inversely associated. Crude incidence rates per 100 person-years over 2 years in patients on OAC versus not on OAC were 0.32 (95% CI 0.14 to 0.71) vs 0.30 (95% CI 0.14 to 0.63) for non-haemorrhagic stroke or systemic embolism, 0.21 (95% CI 0.08 to 0.57) vs 0.17 (95% CI 0.06 to 0.46) for major bleeding, 0.26 (95% CI 0.11 to 0.64) vs 0.26 (95% CI 0.12 to 0.57) for cardiovascular mortality and 0.74 (95% CI 0.44 to 1.25) vs 0.99 (95% CI 0.66 to 1.49) for all-cause mortality. CONCLUSIONS: In contrast to guideline recommendations, almost half of real-world patients with AF at a very low thromboembolic risk according to the CHA2DS2-VASc score receive OAC. Persistent or permanent AF and increasing age up to 65 years are associated with OAC use, while concomitant antiplatelet therapy shows an inverse association. Regardless whether patients received OAC therapy, few thromboembolic and bleeding events occur, highlighting the low risk of this population.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Verbrugge FH, Martin AC, Siegal D, et al. Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk. Heart. 2019. PMID: 31806700. doi:10.1136/heartjnl-2019-315873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。